Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SRTS 
Sensus Healthcare Inc (SRTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SRTS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $11
1 Year Target Price $11
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.21% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.92M USD | Price to earnings Ratio 44.18 | 1Y Target Price 11 |
Price to earnings Ratio 44.18 | 1Y Target Price 11 | ||
Volume (30-day avg) 5 | Beta 1.32 | 52 Weeks Range 4.01 - 9.33 | Updated Date 06/30/2025 |
52 Weeks Range 4.01 - 9.33 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.56% | Operating Margin (TTM) 40.84% |
Management Effectiveness
Return on Assets (TTM) 2.72% | Return on Equity (TTM) 3.46% |
Valuation
Trailing PE 44.18 | Forward PE 44.25 | Enterprise Value 61504874 | Price to Sales(TTM) 2.02 |
Enterprise Value 61504874 | Price to Sales(TTM) 2.02 | ||
Enterprise Value to Revenue 1.56 | Enterprise Value to EBITDA 20.39 | Shares Outstanding 16445000 | Shares Floating 13858807 |
Shares Outstanding 16445000 | Shares Floating 13858807 | ||
Percent Insiders 16.96 | Percent Institutions 26.01 |
Analyst Ratings
Rating 3 | Target Price 11 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sensus Healthcare Inc
Company Overview
History and Background
Sensus Healthcare, Inc. was founded in 2010. It focuses on developing and marketing non-invasive and minimally-invasive treatments for non-melanoma skin cancers and keloids. The company's mission is to provide effective and accessible solutions for patients with these conditions.
Core Business Areas
- Surface Radiotherapy: Sensus designs, manufactures, and markets superficial radiation therapy (SRT) systems used to treat non-melanoma skin cancers, keloids, and other skin conditions. The SRT-100 Vision is their flagship product.
Leadership and Structure
Joe Sardano serves as the Chairman and CEO. The company has a typical corporate structure with departments covering R&D, Sales, Marketing, Operations, and Finance. The Board of Directors provides oversight and guidance.
Top Products and Market Share
Key Offerings
- SRT-100 Vision: The SRT-100 Vision is Sensus Healthcare's flagship product, used for superficial radiation therapy. Competitors include electronic brachytherapy systems and traditional surgical excisions. Market share is estimated to be approximately 25% of the non-invasive skin cancer treatment market. Revenue attributed to this product is not publicly broken down, but it forms the bulk of their sales.
Market Dynamics
Industry Overview
The market for non-melanoma skin cancer treatment is growing due to the aging population and increased awareness. The industry includes surgical, radiation, and topical treatments, with a trend toward less invasive options.
Positioning
Sensus Healthcare positions itself as a leader in non-invasive skin cancer and keloid treatment through SRT. Their competitive advantage lies in their SRT-100 Vision system, which offers a non-surgical alternative.
Total Addressable Market (TAM)
The total addressable market for non-melanoma skin cancer treatment is estimated at several billion USD annually. Sensus is positioned to capture a growing share of this market with its SRT technology.
Upturn SWOT Analysis
Strengths
- Proprietary SRT technology
- Focus on non-invasive treatment
- Growing market for skin cancer treatment
- Established sales and marketing network
Weaknesses
- Reliance on a single product (SRT-100)
- Limited market share compared to traditional treatments
- Potential regulatory hurdles
- High sales and marketing costs
Opportunities
- Expanding applications of SRT technology
- Geographic expansion into new markets
- Partnerships with dermatology clinics and hospitals
- Increased adoption of non-invasive treatments
Threats
- Competition from established medical device companies
- Technological advancements in alternative treatments
- Changes in reimbursement policies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ELEK
- VAR
Competitive Landscape
Sensus has the advantage of specializing in superficial radiation therapy, but faces competition from larger, more diversified companies with broader product portfolios. Their ability to innovate and expand market reach is crucial for maintaining competitiveness.
Growth Trajectory and Initiatives
Historical Growth: Sensus Healthcare has experienced growth in revenue driven by increasing adoption of the SRT-100 system.
Future Projections: Analyst estimates suggest continued growth in revenue and profitability based on increasing market penetration.
Recent Initiatives: Recent initiatives include expanding sales efforts and developing new applications for SRT technology.
Summary
Sensus Healthcare is a specialized medical device company with promising technology in the growing non-melanoma skin cancer treatment market. Its focus on SRT technology offers a non-invasive alternative to traditional treatments, though the reliance on a single product poses a risk. Growth depends on market adoption, geographic expansion, and the ability to compete with larger companies. A focus on improving profitability and diversification will be key for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensus Healthcare Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-06-03 | Co-Founder, Chairman & CEO Mr. Joseph C. Sardano | ||
Sector Healthcare | Industry Medical Devices | Full time employees 54 | Website https://sensushealthcare.com |
Full time employees 54 | Website https://sensushealthcare.com | ||
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.